Noile-Immune Biotech Inc. (4893.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.5x

Market Cap

JPY 6.37B

MomentumView details →

1D Return

+0.00%

YTD Return

+9.02%

RSI (14)

52.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.5x

Market Cap

JPY 6.37B

RSI (14)

52.6

MomentumView details →

1D Return

+0.00%

YTD Return

+9.02%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−20.17%

ROA (TTM)

−19.77%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−28.57%

EPS YoY

+17.76%

FCF YoY

—

Revenue CAGR 3Y

−87.42%

EPS CAGR 3Y

+17.73%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

53.54x

Quick Ratio

53.54x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

−706.00M

Op. CF (TTM)

—

Next earningsNov 12, 2026 →

Latest newsMore news →

Noile-Immune Biotech announced its Q2 FY2026 results for January-June 2026, reporting zero revenue, an operating loss of 419 million yen, an ordinary loss of 370 million yen, and a net loss of 372 million yen.22d ago

Similar companies

PRISM BioLab Co.,LTD206A.T J-Pharma Co.,Ltd.520A.T CellSource Co.,Ltd.4880.T Solasia Pharma K.K.4597.T BrightPath Biotherapeutics Co.,Ltd.4594.T NIPPON CHEMIPHAR CO.,LTD.4539.T Find similar companies →

Latest newsMore news →

Noile-Immune Biotech announced its Q2 FY2026 results for January-June 2026, reporting zero revenue, an operating loss of 419 million yen, an ordinary loss of 370 million yen, and a net loss of 372 million yen.22d ago